OLMA
Olema Pharmaceuticals, Inc.NASDAQHealthcare$15.06-0.40%ClosedMarket Cap: $1.31B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.89
P/S
0.00
EV/EBITDA
-7.30
DCF Value
$0.49
FCF Yield
-11.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-42.9%
ROA
-30.5%
ROIC
-37.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-50.1M | $-46.1M | $-0.51 | — |
| FY 2025 | $0.00 | NaN% | $-178.7M | $-162.5M | $-1.87 | — |
| Q3 2025 | $0.00 | NaN% | $-45.9M | $-42.2M | $-0.49 | — |
| Q2 2025 | $0.00 | NaN% | $-47.9M | $-43.8M | $-0.51 | — |
| Q1 2025 | $0.00 | NaN% | $-34.9M | $-30.4M | $-0.36 | — |
| Q4 2024 | $0.00 | NaN% | $-36.8M | $-33.6M | $-0.57 | — |
| FY 2024 | $0.00 | NaN% | $-142.3M | $-129.5M | $-2.20 | — |
| Q3 2024 | $0.00 | NaN% | $-37.6M | $-34.6M | $-0.60 | — |
| Q2 2024 | $0.00 | NaN% | $-33.5M | $-30.4M | $-0.54 | — |
| Q1 2024 | $0.00 | NaN% | $-34.3M | $-31.0M | $-0.56 | — |
| Q4 2023 | $0.00 | NaN% | $-30.4M | $-26.8M | $-0.49 | — |
| FY 2023 | $0.00 | NaN% | $-105.0M | $-96.7M | $-2.14 | — |